Transitional cell carcinoma (TCC) is the most common tumor affecting canine urinary bladders. It is highly invasive, can obstruct urinary outflow, and has a moderate metastasis rate in areas like lymph nodes and lungs. Several factors increase TCC risk, including older flea products, lawn chemicals, obesity, being female, and certain breeds like Scottish Terriers and Shetland Sheepdogs. Treatment typically involves radiation therapy and chemotherapy rather than surgery due to the tumor’s invasive nature and location. Furthermore, TCC can be targeted with precision therapies enabled by FidoCure such as trametinib and lapatinib.